{"disease":{"id":"antibody-mediated-rejection","name":"antibody mediated rejection"},"drugs":{"marketed":[],"pipeline":[],"offLabel":[],"totalMarketed":0,"totalPipeline":0},"trials":{"data":[{"nct_id":"NCT03408158","title":"HPA Antibodies and the Distribution of Antigen and Antibodies","phase":"NA","overall_status":"COMPLETED","enrollment_count":6170,"lead_sponsor_name":"Guangzhou First People's Hospital","has_results":false},{"nct_id":"NCT03393793","title":"HEart trAnsplantation Registry of piTie-Salpetriere University Hospital","phase":"","overall_status":"COMPLETED","enrollment_count":566,"lead_sponsor_name":"Lee S Nguyen","has_results":false},{"nct_id":"NCT03719339","title":"VIRTUUS Children's Study","phase":"","overall_status":"ACTIVE_NOT_RECRUITING","enrollment_count":445,"lead_sponsor_name":"Children's Hospital of Philadelphia","has_results":false},{"nct_id":"NCT04368962","title":"DSA Risk Factors in MMF-based Immunosuppressed Post-transplanted Patients","phase":"","overall_status":"UNKNOWN","enrollment_count":300,"lead_sponsor_name":"First Affiliated Hospital Xi'an Jiaotong University","has_results":false},{"nct_id":"NCT05140018","title":"Incidence, Course and Outcome of ABMR in Kidney Transplantation","phase":"","overall_status":"UNKNOWN","enrollment_count":225,"lead_sponsor_name":"University Medical Center Groningen","has_results":false},{"nct_id":"NCT05004493","title":"Biorepository and Registry for Plasma Exchange Patients","phase":"","overall_status":"RECRUITING","enrollment_count":200,"lead_sponsor_name":"Charles M Knudson","has_results":false},{"nct_id":"NCT03815864","title":"Antibodies and Liver Retransplantation","phase":"","overall_status":"UNKNOWN","enrollment_count":200,"lead_sponsor_name":"London Health Sciences Centre","has_results":false},{"nct_id":"NCT03744910","title":"Clazakizumab for the Treatment of Chronic Active Antibody Mediated Rejection in Kidney Transplant Recipients","phase":"PHASE3","overall_status":"TERMINATED","enrollment_count":194,"lead_sponsor_name":"CSL Behring","has_results":true},{"nct_id":"NCT06801886","title":"Silymarin's Advantage on Graft Effectiveness","phase":"PHASE3","overall_status":"ENROLLING_BY_INVITATION","enrollment_count":130,"lead_sponsor_name":"University Hospital, Martin","has_results":false},{"nct_id":"NCT06685757","title":"A Study to Learn More About the Effects and Safety of Felzartamab Infusions in Adults With Kidney Transplants Who Have Antibody-Mediated Rejection (AMR)","phase":"PHASE3","overall_status":"RECRUITING","enrollment_count":120,"lead_sponsor_name":"Biogen","has_results":false},{"nct_id":"NCT07444489","title":"A Study to Learn More About the Long-Term Safety and Effects of Felzartamab Infusions in Adults With Kidney Transplants Who Have Antibody-Mediated Rejection (AMR)","phase":"PHASE3","overall_status":"NOT_YET_RECRUITING","enrollment_count":120,"lead_sponsor_name":"Biogen","has_results":false},{"nct_id":"NCT01399593","title":"Safety & Efficacy of Eculizumab to Prevent AMR in Living Donor Kidney Transplant Recipients Requiring Desensitization","phase":"PHASE2","overall_status":"TERMINATED","enrollment_count":102,"lead_sponsor_name":"Alexion Pharmaceuticals, Inc.","has_results":true},{"nct_id":"NCT04026087","title":"Subclass of Donor-specific Antibody as a Risk Factor of Antibody Mediated Rejection in Renal Transplantation","phase":"","overall_status":"COMPLETED","enrollment_count":100,"lead_sponsor_name":"University Hospital, Montpellier","has_results":false},{"nct_id":"NCT05184426","title":"MuLtimodality EvaluatiOn of aNtibody mEdiated Damage in Heart Transplantation (LEONE-HT)","phase":"","overall_status":"ACTIVE_NOT_RECRUITING","enrollment_count":90,"lead_sponsor_name":"Juan Francisco Delgado Jimenez","has_results":false},{"nct_id":"NCT03474536","title":"Quantitative Parameters of HLA-DQ Antibodies in Lung Transplantation","phase":"","overall_status":"COMPLETED","enrollment_count":88,"lead_sponsor_name":"University Hospital, Bordeaux","has_results":false},{"nct_id":"NCT03702257","title":"DSA Intragraft in Lung Transplantation: Diagnostic and Prognostic Value in Antibody Mediated Rejection","phase":"NA","overall_status":"UNKNOWN","enrollment_count":80,"lead_sponsor_name":"University Hospital, Strasbourg, France","has_results":false},{"nct_id":"NCT06112951","title":"A Prospective Randomized Trial of ECP in Subclinical AMR","phase":"NA","overall_status":"RECRUITING","enrollment_count":80,"lead_sponsor_name":"Medical University of Vienna","has_results":false},{"nct_id":"NCT04367610","title":"Effects of A Standardized Treatment Approach on Kidney Transplant Recipients With Antibody-Mediated Rejection","phase":"","overall_status":"COMPLETED","enrollment_count":75,"lead_sponsor_name":"Istanbul University","has_results":false},{"nct_id":"NCT03221842","title":"Efficacy and Safety of Human Plasma-derived C1-esterase Inhibitor as add-on to Standard of Care for the Treatment of Refractory Antibody Mediated Rejection (AMR) in Adult Renal Transplant Recipients","phase":"PHASE3","overall_status":"TERMINATED","enrollment_count":63,"lead_sponsor_name":"CSL Behring","has_results":true},{"nct_id":"NCT02201576","title":"Bortezomib in Rejection of Kidney Transplants","phase":"PHASE2","overall_status":"COMPLETED","enrollment_count":60,"lead_sponsor_name":"Assistance Publique - Hôpitaux de Paris","has_results":false},{"nct_id":"NCT05452317","title":"Assess Burden of Disease Among Kidney Transplant Recipients With Chronic Active Antibody Mediated Rejection","phase":"","overall_status":"COMPLETED","enrollment_count":52,"lead_sponsor_name":"CSL Behring","has_results":false},{"nct_id":"NCT02738918","title":"Belatacept (Nulojix) in Renal Transplant Recipient With Mild Immunologic Risk Factor: a Pilot Prospective Study.","phase":"PHASE2","overall_status":"COMPLETED","enrollment_count":51,"lead_sponsor_name":"Assistance Publique - Hôpitaux de Paris","has_results":false},{"nct_id":"NCT03430414","title":"Analysis of Biopsies With Antibody Mediated Rejection According to the Therapy Response","phase":"","overall_status":"UNKNOWN","enrollment_count":50,"lead_sponsor_name":"Thomas Mueller","has_results":false},{"nct_id":"NCT06744647","title":"Phase 2 Study of ALXN2030 in Patients With Antibody-Mediated Rejection After Kidney Transplantation","phase":"PHASE2","overall_status":"RECRUITING","enrollment_count":45,"lead_sponsor_name":"Alexion Pharmaceuticals, Inc.","has_results":false},{"nct_id":"NCT07134491","title":"Peripheral and Intrarenal B Cell Study in Antibody Mediated Transplant Rejection : Phenotypic and Transcriptional Study, Study of Reactivity","phase":"","overall_status":"RECRUITING","enrollment_count":45,"lead_sponsor_name":"Assistance Publique - Hôpitaux de Paris","has_results":false},{"nct_id":"NCT04897438","title":"Donor-derived Cell-free DNA for Early Diagnosis of Antibody-mediated Rejection","phase":"NA","overall_status":"COMPLETED","enrollment_count":40,"lead_sponsor_name":"Charite University, Berlin, Germany","has_results":false},{"nct_id":"NCT02547220","title":"A Multicenter Study to Evaluate the Efficacy and Safety of Cinryze® for the Treatment of Acute Antibody-mediated Rejection in Participants With Kidney Transplant","phase":"PHASE3","overall_status":"TERMINATED","enrollment_count":39,"lead_sponsor_name":"Shire","has_results":true},{"nct_id":"NCT06990711","title":"A Phase 1 Clinical Trial of Siltuximab for the Treatment of Antibody-Mediated Rejection After Lung Transplantation","phase":"PHASE1","overall_status":"RECRUITING","enrollment_count":30,"lead_sponsor_name":"Washington University School of Medicine","has_results":false},{"nct_id":"NCT07316829","title":"TRAnscriptional Profile of Peripheral Blood Cells in Patient With Chronic Kidney and Lung Rejection: Correlation With Response to Extracorporeal Photo-aphereSiS","phase":"","overall_status":"ACTIVE_NOT_RECRUITING","enrollment_count":30,"lead_sponsor_name":"Fondazione IRCCS Policlinico San Matteo di Pavia","has_results":false},{"nct_id":"NCT04541914","title":"Diagnostic Efficacy of Molecular Diagnostic Method for AMR in ABOiKT","phase":"NA","overall_status":"COMPLETED","enrollment_count":30,"lead_sponsor_name":"Seoul National University Hospital","has_results":false},{"nct_id":"NCT03916822","title":"Cell-based Assays for Antibody-mediated Transplant Rejection","phase":"","overall_status":"UNKNOWN","enrollment_count":30,"lead_sponsor_name":"Plexision","has_results":false},{"nct_id":"NCT03388008","title":"Belatacept Pilot Study in Lung Transplantation Immunosuppression in Lung Transplantation","phase":"PHASE2","overall_status":"COMPLETED","enrollment_count":27,"lead_sponsor_name":"Washington University School of Medicine","has_results":true},{"nct_id":"NCT05021484","title":"Felzartamab in Late Antibody-Mediated Rejection","phase":"PHASE2","overall_status":"COMPLETED","enrollment_count":22,"lead_sponsor_name":"Farsad Eskandary","has_results":false},{"nct_id":"NCT06886646","title":"Allogeneic Umbilical Cord Mesenchymal Stromal Cells for the Treatment of Chronic Antibody-Mediated Rejection in Kidney Transplantation","phase":"PHASE2","overall_status":"NOT_YET_RECRUITING","enrollment_count":22,"lead_sponsor_name":"Assistance Publique - Hôpitaux de Paris","has_results":false},{"nct_id":"NCT04204980","title":"Desensitization in Kidney Allograft Using Daratumumab","phase":"PHASE1, PHASE2","overall_status":"COMPLETED","enrollment_count":21,"lead_sponsor_name":"Assistance Publique - Hôpitaux de Paris","has_results":false},{"nct_id":"NCT03380962","title":"Clazakizumab in Highly-HLA Sensitized Patients Awaiting Renal Transplant","phase":"PHASE1, PHASE2","overall_status":"ACTIVE_NOT_RECRUITING","enrollment_count":20,"lead_sponsor_name":"Stanley Jordan, MD","has_results":false},{"nct_id":"NCT03737136","title":"Comparison Between Bortezomib and Rituximab Plus Plasmapheresis in AMR","phase":"NA","overall_status":"COMPLETED","enrollment_count":20,"lead_sponsor_name":"Shahid Beheshti University of Medical Sciences","has_results":false},{"nct_id":"NCT03444103","title":"A Pilot Trial of Clazakizumab in Late ABMR","phase":"PHASE2","overall_status":"COMPLETED","enrollment_count":20,"lead_sponsor_name":"Medical University of Vienna","has_results":false},{"nct_id":"NCT03436134","title":"Treatment of Chronic Active Antibody Mediated Rejection After Kidney Transplantation by Double-Filtration PlasmaPheresis or Plasma Exchange","phase":"NA","overall_status":"UNKNOWN","enrollment_count":16,"lead_sponsor_name":"University Hospital, Grenoble","has_results":false},{"nct_id":"NCT05913596","title":"The Safety and Efficacy of CD38 Monoclonal Antibody Monotherapy for CaAMR in Renal Transplantation","phase":"NA","overall_status":"UNKNOWN","enrollment_count":15,"lead_sponsor_name":"First Affiliated Hospital of Zhejiang University","has_results":false},{"nct_id":"NCT03380377","title":"Clazakizumab for Chronic and Active Antibody Mediated Rejection Post-Kidney Transplant","phase":"PHASE1, PHASE2","overall_status":"COMPLETED","enrollment_count":10,"lead_sponsor_name":"Stanley Jordan, MD","has_results":true},{"nct_id":"NCT03994783","title":"Transplant Antibody-Mediated Rejection: Guiding Effective Treatments","phase":"PHASE3","overall_status":"TERMINATED","enrollment_count":3,"lead_sponsor_name":"Imperial College London","has_results":false},{"nct_id":"NCT03805178","title":"Lung Transplant Plasmapheresis/Belatacept/Carfilzomib for Antibody Mediated Rejection and Desensitization","phase":"PHASE2","overall_status":"WITHDRAWN","enrollment_count":0,"lead_sponsor_name":"Duke University","has_results":false},{"nct_id":"NCT05862766","title":"Isatuximab in Lung Transplant Recipients","phase":"EARLY_PHASE1","overall_status":"WITHDRAWN","enrollment_count":0,"lead_sponsor_name":"NYU Langone Health","has_results":false},{"nct_id":"NCT02130817","title":"Belatacept in Kidney Transplantation of Moderately Sensitized Patients","phase":"PHASE4","overall_status":"WITHDRAWN","enrollment_count":0,"lead_sponsor_name":"University of Wisconsin, Madison","has_results":false}],"total":45},"guidelines":[],"source":"Drug Landscape verified database"}